A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

The development of an effective HIV vaccine remains an urgent public health need due to the high genetic variability and rapid mutation rates of the virus, which limit the generation of broadly ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna’s been anything but a high-flying ... with applications that include vaccines for HIV, respiratory syncytial virus (RSV), and even personalised cancer treatments. Alas, that investment ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting ...